Saltar al contenido
Merck

Defective myelination in an RNA polymerase III mutant leukodystrophic mouse.

Proceedings of the National Academy of Sciences of the United States of America (2021-09-30)
Emilio Merheb, Min-Hui Cui, Juwen C DuBois, Craig A Branch, Maria Gulinello, Bridget Shafit-Zagardo, Robyn D Moir, Ian M Willis
RESUMEN

RNA polymerase (Pol) III synthesizes abundant short noncoding RNAs that have essential functions in protein synthesis, secretion, and other processes. Despite the ubiquitous functions of these RNAs, mutations in Pol III subunits cause Pol III-related leukodystrophy, an early-onset neurodegenerative disease. The basis of this neural sensitivity and the mechanisms of disease pathogenesis are unknown. Here we show that mice expressing pathogenic mutations in the largest Pol III subunit, Polr3a, specifically in Olig2-expressing cells, have impaired growth and developmental delay, deficits in cognitive, sensory, and fine sensorimotor function, and hypomyelination in multiple regions of the cerebrum and spinal cord. These phenotypes reflect a subset of clinical features seen in patients. In contrast, the gross motor defects and cerebellar hypomyelination that are common features of severely affected patients are absent in the mice, suggesting a relatively mild form of the disease in this conditional model. Our results show that disease pathogenesis in the mice involves defects that reduce both the number of mature myelinating oligodendrocytes and the ability of these cells to produce a myelin sheath of normal thickness. The findings suggest unique sensitivities of oligodendrogenesis and myelination to perturbations of Pol III transcription.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anticuerpo anti-NeuN, clon A60, clone A60, Chemicon®, from mouse
Sigma-Aldrich
Milli-Mark® Anti-Galactocerebroside-FITC Antibody, clone mGalC, clone mGalC, Milli-Mark®, from mouse